DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model
Aims: To explore the cost-effectiveness of alternative methods of screening family members for hypertrophic cardiomyopathy (HCM), the most common monogenic cardiac disorder and the most frequent cause of sudden cardiac death (SCD) in young people.
Methods and results: Economic decision model comparing cascade screening by genetic, as opposed to clinical methods. The incremental cost per life year saved was €14 397 for the cascade genetic compared with the cascade clinical approach. G...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Publisher copy:
- Copyright holder:
- S Wordsworth et al
- Copyright date:
- The full-text of this article is not available in ORA, but you may be able to access the article via the publisher copy link on this record page. Citation: Wordsworth, S. et al. (2010). 'DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model', European Heart Journal 31(8), 926-935. The definitive publisher-authenticated version is available online at http://eurheartj.oxfordjournals.org/.
If you are the owner of this record, you can report an update to it here: Report update to this record